Log in

Relevant bibliographies by topics / Lacosamide / Journal articles

Journal articles on the topic 'Lacosamide'

To see the other types of publications on this topic, follow the link: Lacosamide.

Author: Grafiati

Published: 4 June 2021

Last updated: 11 March 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Lacosamide.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Saria, Marlon G., Courtney Corle, Jethro Hu, Jeremy D. Rudnick, Surasak Phuphanich, Maciej M. Mrugala, Laura K. Crew, et al. "Retrospective analysis of the tolerability and activity of lacosamide in patients with brain tumors." Journal of Neurosurgery 118, no. 6 (June 2013): 1183–87. http://dx.doi.org/10.3171/2013.1.jns12397.

Full text

Abstract:

Object The object of this study was to determine the tolerability and activity of lacosamide in patients with brain tumors. Methods The authors reviewed the medical records at 5 US academic medical centers with tertiary brain tumor programs, seeking all patients in whom a primary brain tumor had been diagnosed and who were taking lacosamide. Results The authors identified 70 patients with primary brain tumors and reviewed seizure frequency and toxicities. The majority of the patients had gliomas (96%). Fifty-five (78%) had partial seizures only, and 12 (17%) had generalized seizures. Most of the patients (74%) were started on lacosamide because of recurrent seizures. Forty-six patients (66%) reported a decrease in seizure frequency, and 21 patients (30%) reported stable seizures. Most of the patients (54 [77%]) placed on lacosamide did not report any toxicities. Conclusions This retrospective analysis demonstrated that lacosamide was both well tolerated and active as an add-on antiepileptic drug (AED) in patients with brain tumors. Lacosamide's novel mechanism of action will allow for concurrent use with other AEDs, as documented by its activity across many different types of AEDs used in this patient population. Larger prospective studies are warranted.

APA, Harvard, Vancouver, ISO, and other styles

2

&NA;. "Lacosamide." Reactions Weekly &NA;, no. 1392 (March 2012): 32. http://dx.doi.org/10.2165/00128415-201213920-00107.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

&NA;. "Lacosamide." Reactions Weekly &NA;, no. 1357 (June 2011): 21. http://dx.doi.org/10.2165/00128415-201113570-00070.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

&NA;. "Lacosamide." Reactions Weekly &NA;, no. 1362 (July 2011): 20. http://dx.doi.org/10.2165/00128415-201113620-00070.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

&NA;. "Lacosamide." Reactions Weekly &NA;, no. 1371 (October 2011): 22–23. http://dx.doi.org/10.2165/00128415-201113710-00079.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

&NA;. "Lacosamide." Reactions Weekly &NA;, no. 1404 (June 2012): 25–26. http://dx.doi.org/10.2165/00128415-201214040-00079.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

&NA;. "Lacosamide." Reactions Weekly &NA;, no. 1406 (June 2012): 27. http://dx.doi.org/10.2165/00128415-201214060-00093.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

&NA;. "Lacosamide." Reactions Weekly &NA;, no. 1413 (August 2012): 31. http://dx.doi.org/10.2165/00128415-201214130-00112.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Cross, Sarah A., and Monique P. Curran. "Lacosamide." Drugs 69, no. 4 (2009): 449–59. http://dx.doi.org/10.2165/00003495-200969040-00005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

&NA;. "Lacosamide." Reactions Weekly &NA;, no. 1316 (August 2010): 28–29. http://dx.doi.org/10.2165/00128415-201013160-00093.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Curia, Giulia, Giuseppe Biagini, Emilio Perucca, and Massimo Avoli. "Lacosamide." CNS Drugs 23, no. 7 (July 2009): 555–68. http://dx.doi.org/10.2165/00023210-200923070-00002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

&NA;. "Lacosamide." Reactions Weekly &NA;, no. 1335 (January 2011): 27. http://dx.doi.org/10.2165/00128415-201113350-00096.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

&NA;. "Lacosamide." Reactions Weekly &NA;, no. 1343 (March 2011): 23. http://dx.doi.org/10.2165/00128415-201113430-00082.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Cada, Dennis J., Terri L. Levien, and Danial E. Baker. "Lacosamide." Hospital Pharmacy 44, no. 6 (June 2009): 497–508. http://dx.doi.org/10.1310/hpj4406-497.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Gupta, Sushilkumar Satish, Ravikaran Patti, Daniel Lindsay, Hitesh Raheja, and Yizhak Kupfer. "Lacosamide." American Journal of Therapeutics 25, no. 6 (November 2018): e729-e730. http://dx.doi.org/10.1097/mjt.0000000000000745.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Doty, Pamela, G. David Rudd, Thomas Stoehr, and Dirk Thomas. "Lacosamide." Neurotherapeutics 4, no. 1 (January 2007): 145–48. http://dx.doi.org/10.1016/j.nurt.2006.10.002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

&NA;. "Lacosamide." Reactions Weekly &NA;, no. 1424 (October 2012): 33. http://dx.doi.org/10.2165/00128415-201214240-00111.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Perucca, Emilio, Uma Yasothan, Gilbert Clincke, and Peter Kirkpatrick. "Lacosamide." Nature Reviews Drug Discovery 7, no. 12 (December 2008): 973–74. http://dx.doi.org/10.1038/nrd2764.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

McIntyre, J. A., J. Castañer, and L. Martín. "Lacosamide." Drugs of the Future 29, no. 10 (2004): 992. http://dx.doi.org/10.1358/dof.2004.029.10.848936.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Labau, Julie I. R., Matthew Alsaloum, Mark Estacion, Brian Tanaka, Fadia B. Dib-Hajj, Giuseppe Lauria, Hubert J. M. Smeets, Catharina G. Faber, Sulayman Dib-Hajj, and Stephen G. Waxman. "Lacosamide Inhibition of NaV1.7 Channels Depends on its Interaction With the Voltage Sensor Domain and the Channel Pore." Frontiers in Pharmacology 12 (December 21, 2021). http://dx.doi.org/10.3389/fphar.2021.791740.

Full text

Abstract:

Lacosamide, developed as an anti-epileptic drug, has been used for the treatment of pain. Unlike typical anticonvulsants and local anesthetics which enhance fast-inactivation and bind within the pore of sodium channels, lacosamide enhances slow-inactivation of these channels, suggesting different binding mechanisms and mode of action. It has been reported that lacosamide’s effect on NaV1.5 is sensitive to a mutation in the local anesthetic binding site, and that it binds with slow kinetics to the fast-inactivated state of NaV1.7. We recently showed that the NaV1.7-W1538R mutation in the voltage-sensing domain 4 completely abolishes NaV1.7 inhibition by clinically-achievable concentration of lacosamide. Our molecular docking analysis suggests a role for W1538 and pore residues as high affinity binding sites for lacosamide. Aryl sulfonamide sodium channel blockers are also sensitive to substitutions of the W1538 residue but not of pore residues. To elucidate the mechanism by which lacosamide exerts its effects, we used voltage-clamp recordings and show that lacosamide requires an intact local anesthetic binding site to inhibit NaV1.7 channels. Additionally, the W1538R mutation does not abrogate local anesthetic lidocaine-induced blockade. We also show that the naturally occurring arginine in NaV1.3 (NaV1.3-R1560), which corresponds to NaV1.7-W1538R, is not sufficient to explain the resistance of NaV1.3 to clinically-relevant concentrations of lacosamide. However, the NaV1.7-W1538R mutation conferred sensitivity to the NaV1.3-selective aryl-sulfonamide blocker ICA-121431. Together, the W1538 residue and an intact local anesthetic site are required for lacosamide’s block of NaV1.7 at a clinically-achievable concentration. Moreover, the contribution of W1538 to lacosamide inhibitory effects appears to be isoform-specific.

APA, Harvard, Vancouver, ISO, and other styles

21

"Lacosamide." Reactions Weekly 1842, no. 1 (February 2021): 222. http://dx.doi.org/10.1007/s40278-021-90958-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

"Lacosamide." Reactions Weekly 1841, no. 1 (February 2021): 136. http://dx.doi.org/10.1007/s40278-021-90638-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

"Lacosamide." Reactions Weekly 1847, no. 1 (March 2021): 267. http://dx.doi.org/10.1007/s40278-021-92824-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

"Lacosamide." Reactions Weekly 1923, no. 1 (September 10, 2022): 276. http://dx.doi.org/10.1007/s40278-022-23139-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

"Lacosamide." Reactions Weekly 1909, no. 1 (June 2022): 314. http://dx.doi.org/10.1007/s40278-022-16601-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

"Lacosamide." Reactions Weekly 1909, no. 1 (June 2022): 315. http://dx.doi.org/10.1007/s40278-022-16602-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

"Lacosamide." Reactions Weekly 1905, no. 1 (May 2022): 271. http://dx.doi.org/10.1007/s40278-022-14661-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

"Lacosamide." Reactions Weekly 1858, no. 1 (June 2021): 220. http://dx.doi.org/10.1007/s40278-021-96938-z.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

"Lacosamide." Reactions Weekly 1879, no. 1 (October 2021): 198. http://dx.doi.org/10.1007/s40278-021-04682-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

"Lacosamide." Reactions Weekly 1879, no. 1 (October 2021): 199. http://dx.doi.org/10.1007/s40278-021-04683-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

"Lacosamide." Reactions Weekly 1891, no. 1 (January 2022): 180. http://dx.doi.org/10.1007/s40278-022-09432-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

"Lacosamide." Reactions Weekly 1902, no. 1 (April 2022): 261. http://dx.doi.org/10.1007/s40278-022-13405-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

"Lacosamide." Reactions Weekly 1894, no. 1 (February 2022): 197. http://dx.doi.org/10.1007/s40278-022-10310-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

"Lacosamide." Reactions Weekly 1583, no. 1 (January 2016): 667. http://dx.doi.org/10.1007/s40278-016-13230-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

"Lacosamide." Reactions Weekly 1583, no. 1 (January 2016): 669. http://dx.doi.org/10.1007/s40278-016-13231-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

"Lacosamide." Reactions Weekly 1687, no. 1 (February 2018): 127. http://dx.doi.org/10.1007/s40278-018-41548-z.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

"Lacosamide." Reactions Weekly 1706, no. 1 (June 2018): 293. http://dx.doi.org/10.1007/s40278-018-47622-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

"Lacosamide." Reactions Weekly 1707, no. 1 (June 2018): 173. http://dx.doi.org/10.1007/s40278-018-47989-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

"Lacosamide." Reactions Weekly 1708, no. 1 (June 2018): 201. http://dx.doi.org/10.1007/s40278-018-48294-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

"Lacosamide." Reactions Weekly 1708, no. 1 (June 2018): 202. http://dx.doi.org/10.1007/s40278-018-48295-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

"Lacosamide." Reactions Weekly 1709, no. 1 (July 2018): 136. http://dx.doi.org/10.1007/s40278-018-48547-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

"Lacosamide." Reactions Weekly 1712, no. 1 (July 2018): 324. http://dx.doi.org/10.1007/s40278-018-49613-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

"Lacosamide." Reactions Weekly 1712, no. 1 (July 2018): 325. http://dx.doi.org/10.1007/s40278-018-49614-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

"Lacosamide." Reactions Weekly 1718, no. 1 (September 2018): 142. http://dx.doi.org/10.1007/s40278-018-51486-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

"Lacosamide." Reactions Weekly 1718, no. 1 (September 2018): 143. http://dx.doi.org/10.1007/s40278-018-51487-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

"Lacosamide." Reactions Weekly 1720, no. 1 (September 2018): 152. http://dx.doi.org/10.1007/s40278-018-51946-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

"Lacosamide." Reactions Weekly 1722, no. 1 (October 2018): 199. http://dx.doi.org/10.1007/s40278-018-52528-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

"Lacosamide." Reactions Weekly 1630, no. 1 (December 2016): 149. http://dx.doi.org/10.1007/s40278-016-23673-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

"Lacosamide." Reactions Weekly 1630, no. 1 (December 2016): 150. http://dx.doi.org/10.1007/s40278-016-23674-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

"Lacosamide." Reactions Weekly 1633, no. 1 (January 2017): 434. http://dx.doi.org/10.1007/s40278-017-24702-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!